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Uveitis is a major cause of visual impairment and blindness among working-age adults, ac-
counting for 10% of legal blindness in the United States. Among people with MS, the preva-
lence of uveitis is 10 times higher than among the general population, and because MS and
uveitis share similar genetic risk factors and immunologic effector pathways, it is not clear
whether uveitis is one of the manifestations of MS or a coincident disorder. This uncertainty
raises several diagnostic and management issues for clinicians who look after these patients,
particularly with regard to recognizing visual symptoms resulting from demyelination, in-
traocular inflammation, or the visual complications of disease modifying drugs for MS, e.g.,
fingolimod. Likewise, management decisions regarding patients with uveitis are influenced by
the risk of precipitating or exacerbating episodes of demyelination, e.g., following anti–tumor
necrosis factor biologic therapy, and other neurologic complications of immunosuppressive
treatments for uveitis. In this review, we explore the similarities in the pathophysiology, clinical
features, and treatment of patients with uveitis andMS. Based on the latest evidence, we make a
set of recommendations to help guide neurologists and ophthalmologists to best manage
patients affected by both conditions.
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Uveitis is a major cause of visual impairment and blindness
among working-age adults, accounting for 10% of legal blind-
ness in the United States.1 Uveitis is traditionally defined as
inflammation of the uveal tract, although inflammation is not
confined to the uvea; consequently, uveitis is now defined an-
atomically based on the principal sites of inflammation: anterior
uveitis affects the iris and ciliary body; intermediate uveitis (IU)
predominantly affects the vitreous; posterior uveitis affects the
retina and/or choroid; and panuveitis refers to anterior, in-
termediate, and posterior uveitis combined.2 The incidence of
uveitis varies between 17.4 and 52.4 cases per 100,000 person
years, and the prevalence between 69.0 to 114.5 per 100,000
persons,3 but among patients with MS, the prevalence is 1%.4
MS is an inflammatory demyelinating disease of the CNS, af-
fecting almost 2.5 million people worldwide.5 It is frequently
associated with visual symptoms caused by demyelinating le-
sions of afferent and efferent visual pathways. IU is the uveitis
subtype most commonly associated with MS, but because
retinal neurons are normally unmyelinated, IU is not a conse-
quence of demyelination. Yet it is still not known whether IU is
one of the manifestations of MS or a coincident disorder. This
raises several diagnostic and management issues for clinicians
who look after patients affected by both disorders with regard
to recognizing visual symptoms resulting from demyelination,
intraocular inflammation, or the complications of treatment.
This review summarizes the common pathophysiology and
clinical features of IU andMS to draw inferences regarding the
optimal management of patients affected by both conditions.
Common pathways in the
pathogenesis of MS and IU
The eye and brain are immune-privileged sites, created by tight
junctions between vascular endothelial cells and the cytokine
milieu. Inflammation occurs through breakdown of the normal
immunoregulatory mechanisms in the eye and brain. Although
it is still unclear what triggers inflammation in both conditions,
several sources of evidence suggest that they share similar risk
factors and immunologic effector pathways.6,7
Common risk factors for MS and IU
Environmental risk factors, including exposure to Epstein-Barr
virus, smoking, northern latitude, and low vitamin D are as-
sociated withMS,7 with evidence for an immunoregulatory role
of the gut microbiome.8 These risk factors are not linked to IU,
although the etiology of uveitis varies worldwide: 30%–50% of
cases are caused by infection in developing nations, whereas a
greater proportion are attributed to noninfectious, immune-
mediated mechanisms in higher-income countries.3
The associations between MS and uveitis with infection support
the hypothesis that they may be triggered by infectious agents in
genetically susceptible individuals. Genome-wide association
studies have identified loci accounting for up to 30% of an indi-
vidual’s risk ofMS,7 andmany overlap with genetic risk factors for
IU, notably, human leukocyte antigen (HLA) class II genes,HLA-
DR15 and HLA-DR-51.4 Other shared genetic risk loci provide
clues to immunologic effector pathways common to both disor-
ders: tumor necrosis factor (TNF, rs361525, rs1800629), lym-
photoxin alpha (rs909253), interleukin 6 (IL-6, rs1800795), IL-2/
IL-21 (rs6822844), IL-2 receptor alpha (rs2104286, rs12722489),
interferon regulatory factor 5 (rs10954213),7,9,10 and through one
genetic linkage study, functional variants affecting TNF receptor
superfamily members 10a and 13b (B cell–activating factor),
G-protein subunit gamma transducing-1, alpha-2-macroglobulin
domain containing-8, diacylglycerol kinase iota and reelin.11 Fur-
ther support for their role in MS and uveitis pathogenesis comes
from animal models (section Common immunologic effector
mechanisms in MS and IU, figures 1 and 2).
Common immunologic effectormechanisms in
MS and IU
Experimental autoimmune uveitis (EAU) and experimental
autoimmune encephalitis (EAE) are commonly used animal
models of uveitis andMS, respectively, and there is evidence for
cross-reactivity between the antigens used to precipitate them.
Transient bilateral anterior uveitis occurs in EAE induced by
myelin basic protein (MBP),12 whereas panuveitis occurs in
EAE induced with S100B.13MBP is also used to induce EAU.14
These experimental data imply some commonality in the
precipitants of MS and uveitis that is further supported by
evidence of autoreactive T cells from patients with MS dis-
playing proliferative responses to retinal arrestin.15
In the eye (figure 1), the ocular microenvironment normally
favors T-cell differentiation to the regulatory FoxP3+ (Treg)
phenotype, maintaining ocular immune privilege.16 Likewise,
FoxP3+ Tregs, Tr1 cells, and a subset of regulatory B cells
(Bregs)17,18 limit immune activation in the brain (figure 2).
However, compartmentalization of autoantigens in the eye
and brain impairs the development of peripheral tolerance in
autoreactive T cells, which can then precipitate uveitis andMS
relapses. Evidence from EAU models suggests activated
Glossary
CSCR = central serous chorioretinopathy; EAE = experimental autoimmune encephalitis; EAU = experimental autoimmune
uveitis; HLA = human leukocyte antigen; IU = intermediate uveitis; MBP = myelin basic protein; MMF = mycophenolate
mofetil; OCT = optical coherence tomography; RRMS = relapsing-remitting MS; Th1 = T-helper 1; TNF = tumor necrosis
factor.
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pathogenic T cells entering the eye fail to respond to regu-
latory cues and contribute to immune-mediated tissue dam-
age via release of reactive oxygen species, nitric oxide
synthesis, and cell-mediated damage.16 Progressive forms of
MS are similarly thought to represent compartmentalized
immune responses: B cells, microglia, and astrocytes may
initiate the immune response, but trafficking of immune cells
from the periphery becomes less important as disease pro-
gression becomes independent of these cells and progressive
mitochondrial injury, oxidative stress, and ion channel re-
distribution ensue.17,18
Key effector cells in uveitis andMS relapses include distinct subsets
of CD4+ T-helper 1 (Th1) cells producing signature cytokines
interferon (INF)-γ and TNF-α andCD4+ T cells producing IL-17
(Th17).6,19 These cytokines activate an acute inflammatory cas-
cade with recruitment of macrophages and neutrophils.6 In addi-
tion, CD8+ T cells and B cells are implicated: in postmortem
specimens from patients with MS, CD8+ T cells are significantly
enriched in perivascular cuffs and acute parenchymal lesions.20
Furthermore, 90% of patients with MS have oligoclonal bands in
their CSF (intrathecally synthesized IgG),21 and lymph node–like
follicles containing B cells have been identified adjacent to cortical
Figure 1 Model for uveitis immunopathogenesis and the effects of immunotherapies on its mediators
Uveitis is considered to be a T cell–mediated disease driven by CD4+ Th1/Th17 cells. Release of major cytokines, IL-17 and IFN-γ, activates inflammatory
cascades, which disrupt the blood-retinal barrier, and causes local tissue damage via reactive oxygen species (ROS), nitric oxide synthesis (NOS), and cell-
mediated damage. Antigen-presenting cells (APCs) activate CD4 T cells and are further activated by their respective cytokines, which accentuate their function.
Pathogenic B-cell populations are less well described, but also contribute to uveitis manifestations in humans via antigen specific autoimmunity and release
of proinflammatory cytokines. Regulatory cells, including FoxP3+ Treg cells, suppress or control the manifestations of uveitis. Therapeutic agents with their
proposed actions on key pathways in uveitis are highlighted in this figure. AZT = azathioprine; ALM = alemtuzumab; CYPH = cyclophosphamide; FLM =
fingolimod; IFN = interferon; MMF = mycophenolate mofetil; MTX = methotrexate; NTZ = natalizumab; RTX = rituximab; SKM = secukinumab; TCZ =
tocilizumab; TLM = tacrolimus; USK = ustekinumab.
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MS lesions.22 Likewise, B-cell inflammatory infiltrates have been
demonstrated in aqueous samples and chorioretinal biopsies from
patients with active uveitis,6,23 and lymph node–like follicles can be
found in the eyes of some patients with persistent uveitis.24 Hence,
similar immune cell populations (CD4+Th1 andTh17 cells, CD8+
cytotoxic T cells, Tregs, B cells, macrophages, and NK cells) and
cytokines (TNF, IFNγ, IL-2, IL-6, IL-10, IL-12, IL-17, and IL-21/
22/23) are involved in the pathogenesis of MS and uveitis (sum-
marized in figures 1 and 2).
Shared clinical features of MS and IU
Diagnostic criteria
IU accounts for 10%–20% of uveitis cases overall, but
61%–80% of MS-associated uveitis.3,11 At present, MS-
associated uveitis is not defined separately from un-
differentiated (formerly idiopathic) IU, a term normally re-
served for anatomically defined IU that is not associated with
infection or systemic diseases, like sarcoidosis or Behçet
Figure 2 Model for MS immunopathogenesis and effects of immunotherapies on its mediators
Episodes of acute demyelination in relapsing-remittingMS aremediated by T cells and B cells. The effector T cells are CD4+ Th1/Th17 cells, which release their
respective lineage cytokines and promote further disease manifestations via their direct effects on CD8+ T cells and their indirect effects caused by cytokine
release, for example, leading to the augmentation of APC function. They are activated in the periphery and reactivated in the CNS. Effector pathogenic B-cell
populations form local lymphoid follicle–like collections within the CNS as disease becomes progressive, leading to the formation of plasma cells, which
generate Igs and oligoclonal bands detected in the CNS. Innate immune cells such as APCs activate T-cell populations and are further activated by the
cytokines released by CD4 T cells and pathogenic B cells. Natural killer cells have both pro- and anti-inflammatory roles in MS but form part of the regulatory
milieu. Regulatory T-cell populations include the FoxP3+ Treg cells and CD4+ Tr1 cells, which produce anti-inflammatory cytokines and inhibit effector CD4+
T cells. Disease-modifying drugs forMS act by blocking leukocyte trafficking, e.g., FLM andNTZ, or they directly suppress pathogenic B cells and effector T-cell
populations, e.g., TFN, CDN, and ALM, or they inhibit proinflammatory cytokines, e.g., IFN-β and DMF, or they suppress B cells by blocking CD20 activity, e.g.,
RTX andOCZ. ALM = alemtuzumab; APC = antigen-presenting cell; CDN = cladribine; DMF = dimethyl fumarate; FLM = fingolimod; IFN-β = interferon-beta; Ig =
immunoglobulin; NTZ = natalizumab; OCZ = ocrelizumab; RTX = rituximab; TFN = teriflunomide.
4 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 1 | January 2021 Neurology.org/NN
disease.2 This is because a sizable proportion of people first
diagnosed with IU might develop MS several years later.4
Neuroimaging is not currently recommended for patients
with IU unless they already have neurologic symptoms or
signs or they are being evaluated for certain biologic therapies
(section Recommendations for management of MS-
associated IU).25 Consequently, there are no known pre-
dictive clinical or investigation findings to identify those
people with IU at greater risk of developing MS later. Because
of the difficulties in definingMS-associated IU in patients who
do not already have MS, the most conservative approach is to
use the latest 2017 McDonald criteria for MS5 and the ana-
tomic definition of undifferentiated IU by the Standardization
of Uveitis Nomenclature Group.2
Shared clinical symptoms and signs
The clinical presentation of IU differs from demyelinating
lesions of the afferent and efferent visual pathways. Patients
with IU may be asymptomatic for several years or develop
symptoms insidiously. The most common symptoms (if they
occur) are floaters, blurred vision, pain, photophobia, and red
eye. Although symptoms of eye pain, blurred vision, and
photophobia are also experienced by patients with acute optic
neuritis (which affects 30%–50% of patients with MS),26 they
normally start to improve spontaneously after a few weeks,
although some degree of optic atrophy, reduced acuity, color
vision, visual field, and contrast sensitivity may be long-term
outcomes. In contrast, symptoms of IU tend to persist
Figure 3 Fundal changes associated with intermediate uveitis and the complications of treatment
Fundus photographs (A and B) and corresponding OCT images (C and D) taken from the same patient before (A and C) and after (B and D) treatment for IU. (A
and C) Pretreatment images showhow severe active vitritis makes the fundal view hazy (A) and blur OCT images of the retina (C). Thewhite asterisk highlights
the appearance of vitritis onOCT,which looks like a gray snowstorm. Thewhite arrowpoints to coincident neuroretinitis causing retinal thickening in the same
patient. (B and D) Posttreatment images show how the resolution of active vitritis mean that the fundal view (B) and OCT image of the retina (D) become
clearer and the vitreous appears black (yellow asterisk). (E) OCT image showing cystoidmacular edema: a complication of IU and fingolimod. The white arrow
points to intraretinal cystic spaces and retinal thickening. (F) OCT image of central serous chorioretinopathy: a complication of steroid treatment. The yellow
arrow points to subretinal fluid. (G) Two MRI brain slices from the same patient who developed demyelination following exposure to anti-TNF biologic
therapy, demonstrating high T2 signal in the periventricular and deep white matter. Images are supplied courtesy of Dr. C. Rice, Dr. L. Kobayter, and Mr. T.
Burke. IU = intermediate uveitis; OCT = optical coherence tomography.
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without treatment and are more likely to be confused with
chronic optic neuropathy associated with progressive forms of
MS.26 However, IU is not associated with an RAPD, unless it
becomes complicated by optic disc edema (which is un-
common). Nor is undifferentiated IU associated with any
neurologic symptoms. Examination findings include vitreous
opacities (snowballs), exudates around the vitreous base or
ora serrata (snowbanking), and peripheral periphlebitis,
sometimes associated with vitreous hemorrhages.27
Clinical course
Although IU typically affects both eyes, it usually has a good long-
term visual prognosis. For example, theMulticenterUveitis Steroid
Trial found that patients with IU had a relatively good prognosis,
except when macular thickening and edema were detected on
optical coherence tomography (OCT) scans combinedwith active
inflammation (figure 3C).28 Moreover, a retrospective case review
at a tertiary center found that 22.5% of patients with IU did not
require treatment, and 60% had relatively preserved visual acuity
after 10 years of follow-up.29 Hence, the aim of management is to
treat sight-threatening features (not uncomplicated or asymp-
tomatic IU) such as glaucoma, cataract, epiretinal membrane, optic
disc edema, retinal vasculitis, and retinal detachment. As these
complications can develop insidiously, regular follow-up by an
ophthalmologist is required to manage them.
Typically, the onset of MS-associated IU is in middle age.
Patients with MS-associated IU are more commonly female
Table 1 Disease-modifying therapies for MS
Therapy Mechanism of action Clinical and experimental evidence Visual side effects
Interferon-beta Cytokine with pleiotropic effects,
appears to limit the actions of IL-
17 and IFN-gamma.
Reduced inflammation in EAE.e1,e2 Evidence from trials of
reduced disease progression in RRMS.e3-5
Interferon-related retinopathy.
Higher risk in patients with
diabetes and hypertension.
Glatiramer A synthetic polypeptide, competes
with myelin antigens for T-cell
presentation.e6
Inhibited EAE induction in different species.e6 Evidence
from trials of reduced disease progression in RRMS.e7
No significant visual side effects.
Teriflunomide Inhibits B- and T-cell proliferation
by inhibition of pyrimidine
synthesis.
Reduced demyelination and inflammation in the RRMS
animal model.e8 Reduced relapse rate of RRMS.e9,e10
No visual side effects.
Cladribine T- and B-cell depletion via
impaired DNA metabolism.e11
Attenuated EAE by interfering with IL-beta-1 activity.e12
Reduced relapse rate in RRMS.e13
No significant visual side effects.
Natalizumab mAb interfering with leukocyte
migration via inhibition of alpha4-
integrin
Reduction of activated lymphocyte migration in EAE.e14
Reduced relapse rate, disability progression, and
demyelination on MRI scans in RRMS.e15,16





upregulation of the transcription
factor Nrf2.
Suppresses IFN-gamma and IL-17–producing CD4+ cells in
EAE.e18 Reduced relapse rate in RRMS.e19,e20
PML has been linked to DMF.
Fingolimod Nonselective S1P receptor
modulator, limits lymphocyte
trafficking.
Inhibits EAE disease development.e21,e22 Reduced RRMS
inflammatory disease activity, limited effect on
disability.e23,e24
Macular edema in <0.5%. PML.
Siponimode25 Selective S1P receptor modulator.
Similar mechanism to fingolimod.
Reduced inflammatory disease activity in RRMSe26 and
disability progression in patients with SPMS.e25
Macular edema in 2%. Possible
risk of PML.
Alemtuzumabe27 Anti-CD52 monoclonal antibody
causing T- and B-lymphocyte
depletion.
Reduced demyelination and axonal loss in EAE.e28
Reduced RRMS disease progression and relapse rate.e29-31
Autoimmune diseases,
particularly thyroid disease.
Rituximab* Anti-CD20 monoclonal antibodies
predominantly targeting maturing
B-cell populations.
Evidence of efficacy in PPMS and RRMS.e32,e33 No significant visual side effects.
Ocrelizumab* Patients with PPMS and RRMS had reduced rates of clinical
and MRI progression.e34,e35
Mitoxantrone* Topoisomerase II inhibiting
chemotherapy agent.
Prevents EAE onset if administered during the induction
phase.e36,e37 Reduced relapse rate and progression in
RRMS, SPMS, and PPMS.38–40
Acute promyelocytic leukemia







Evidence for reduced relapse rate and progression in
multicenter trials for RRMS.e41 Ongoing trials for PPMS
and SPMS.
Cataract formation
Abbreviations: EAE = experimental autoimmune encephalitis; mAb = monoclonal antibody; PML = progressive multifocal leukoencephalopathy; PPMS =
primary progressive MS; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS.
All therapies in the table are used to treat RRMS.
Starred therapies (*) are also used in management of PPMS and SPMS.
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with relapsing-remitting MS (RRMS); however, these fea-
tures likely reflect the female preponderance and higher
prevalence of RRMS overall. The prevalence of periphlebitis
and other vasculitic changes in the retinal periphery is re-
portedly higher in patients with IU with MS compared with
those without, although their clinical significance is uncertain
because the visual prognosis of IU in patients with or without
MS appears to be similar.29
It is not known whether IU is a predictor of worse MS dis-
ability as reports have been conflicting.4,30 A thinner retinal
nerve fiber layer on OCT imaging is linked to worse MS
disability,31 but because patients were not stratified by those
with or without IU, the association is likely to reflect previous
episodes of optic neuritis rather than IU. The relapse rate is
higher in patients with MS with uveitis in clinical trials of
fingolimod.32 Hence, it is possible that patients with MS-
associated IU may have different MS prognostic or treatment
outcomes, but the evidence in this area is still lacking.
Shared treatment approaches in the
management of MS and IU
Available treatments for MS and IU aim to reduce symptoms
and cumulative visual or neurologic disability, but the com-
plications of treatment can also affect visual and neurologic
function (tables 1 and 2). The unintended consequences of
treatment need careful differentiation from disease relapses or
progression because their management will differ.33 The
multidisciplinary management of patients by a neurologist
and ophthalmologist is recommended for the best outcomes.
Management of acute relapses of MS and IU
In the acute setting, MS relapses and sight-threatening in-
flammation in IU are both managed with corticosteroids. Oral or
IVmethylprednisolonewill shorten the duration of anMS relapse,
but does not have any meaningful impact on long-term neuro-
disability.5 Systemic steroids are used to treat acute relapses of IU;
but unlike MS, intraocular inflammation is amenable to local
therapy. Topical steroid drops do not penetrate the posterior
segment of the eye, but periocular steroid injections or intravitreal
injection of steroid implant are viable alternatives, which avoid the
side effects of systemic corticosteroids. Moreover, the effects of
intravitreal steroid implants can last up to 6 months.34
Important considerations are the possible complications of
corticosteroid treatment and how they may be distinguished
from relapses of MS or IU. Corticosteroids can cause systemic
symptoms that may be confused with progressive neuro-
disability from MS. Likewise, frequent or chronic treatment
with local or systemic corticosteroids can cause sight-
threatening complications, like cataract, glaucoma and, cen-
tral serous chorioretinopathy (CSCR).
Cataracts cause progressive reduction in visual acuity, contrast
sensitivity, night vision, and color perception, which might be
confused with optic neuropathy. Nevertheless, cataracts are
not a contraindication to steroid treatment, and cataract
surgery will restore vision. Glaucoma also causes insidious
visual loss that is largely asymptomatic until advanced. It is a
progressive optic neuropathy that is distinguished from de-
myelinating optic neuropathy based on characteristic optic
nerve cupping. However, glaucoma can be treated medically
and/or surgically to prevent permanent visual loss and rep-
resents a relative contraindication to local steroid treatment.33
Importantly, cataracts and glaucoma are also common sight-
threatening complications of IU.
CSCR is another complication of local/systemic steroid
treatment. The population incidence of CSCR is 9.9 per
100,000 in men and 1.7 per 100,000 in women, but among
patients on long-term steroids, the prevalence is as high as
1%–6%.35 CSCR causes symptoms of visual distortion and
central visual loss, and OCT imaging shows subretinal fluid
in the central macular region (figure 3F). The condition is
generally reversible following steroid withdrawal, but rep-
resents a relative contraindication to steroid treatment
because chronic CSCR can lead to permanent visual loss.35
Without OCT imaging, the condition may be confused
with macular edema associated with active inflammation in
IU or the side effect of certain disease modifying drugs
(DMDs) for MS, e.g., fingolimod (figure 3E, section Im-
munomodulatory drugs for MS and IU).
Immunomodulatory drugs for MS and IU
Patients with MS with frequent relapses and patients with IU
with sight-threatening or steroid-resistant disease may require
additional immunomodulatory therapies. Several DMDs
are now available to reduce the frequency of relapses in
RRMS, and recent trials have shown promise for ocrelizumab
and siponimod in primary and secondary progressive
MS18,36,37(summarized in figure 2 and table 1). Similarly, a
range of immunomodulatory treatments for the whole spec-
trum of uveitic disorders is available for inflammation re-
fractory to local or systemic steroids (summarized in table 2
and figure 1).38 As large clinical trials of medical treatments
for uveitis normally include heterogeneous groups of patients
with different uveitis subtypes, the choice of medical treat-
ment for IU specifically is more difficult. Expert consensus
statements are available, albeit not specific to IU.38 Most
first-line immunosuppressants used to treat uveitis act by
suppressing T- and B-cell activation and/or proliferation.
Anti-TNF biologic therapies are usually reserved for patients
with uveitis with disease refractory to first-line immunosup-
pressants, but there is a risk of precipitating demyelination
(see below).38 The case for first-line anti-TNF treatment is
stronger in patients with uveitis with other systemic diseases
like Behçet disease.
Few studies have specifically examined the impact of estab-
lished treatments for IU on MS or MS on IU, but as many
immunomodulatory treatments for MS and uveitis target the
same effector cells and/or leukocyte trafficking from the
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blood to the CNS, there is great potential for these agents in
treating patients with coexistent disease. IFN-α is an effective
treatment for uveitis, particularly associated with Behçet
disease, but there is weaker evidence for the efficacy of IFN-β
in uveitis.38 Isolated case reports and retrospective studies
have reported improvements in patients with IU co-
incidentally started on glatiramer acetate or mycophenolate
mofetil (MMF) for the management of MS, although evi-
dence for MMF is much stronger in uveitis than MS. Aza-
thioprine has been used to treat both MS and uveitis, but the
evidence base is weaker.38–40 Studies of EAU support the use
of fingolimod during active uveitis,41 but as human clinical
trial data are currently lacking, one must weigh the benefits
against the risk of ocular complications (see below). Fur-
thermore, the relapse rate is higher in patients with MS with
uveitis in clinical trials of fingolimod.32 More recently,
anti–IL-6 receptor monoclonal antibodies (tocilizumab) and
anti–IL-17 therapy (secukinumab) have been considered as
additional options for treatment-refractory uveitis.42 Toci-
lizumab reduces inflammation in EAE and has been used to
treat patients with neuromyelitis optica, suggesting that
tocilizumab might be a good option in the treatment of both
conditions.43,44 In 1 patient with tumefactive MS, treatment
with natalizumab led to near-complete resolution of co-
incident IU,45 but there are no clinical trials supporting the
use of natalizumab in IU. Alemtuzumab, which inhibits the
activation of effector T cells in the peripheral circulation, has
been reported to improve treatment-refractory uveitis.46
Furthermore, anti-CD20 therapies have been shown to be
independently effective in uveitis and MS.18,47
The main limitation for using DMDs designed for MS to treat
patients with uveitis is the risk of causing visual complications.
These complications need to be distinguished from de-
myelinating optic neuropathy and IU (table 1). Macular
edema associated with S1P inhibitors is the most significant:
approximately 0.2% of patients on fingolimod develop mac-
ular edema within the first 6 months of treatment, and the
incidence may be higher in patients with diabetes mellitus.
Baseline OCT imaging is recommended before initiation of
Table 2 Immunomodulatory therapies for the treatment of uveitis
Therapy Mechanism of action Clinical and experimental evidence Neurologic side effects
Methotrexate Antimetabolite inhibiting
dihydrofolate reductase and folate
metabolism and thymidine
synthesis.
Inhibited development of EAU in guinea
pigs.e42 Steroid-sparing effect to control
inflammation in uveitis.e43-45
Nonspecific neurologic side effects.
Azathioprine Antimetabolite, mercaptopurine
derivative inhibiting DNA replication,
and purine synthesis.
Moderate inflammation control as steroid-
sparing agent.e46-48






and cytostatic effect on T and B
lymphocytes.
Inhibited EAU inmice.e49 Inflammation control
and steroid-sparing effect in uveitis.e50-52
Nonspecific neurologic side effects.
Risk of progressive multifocal
leukoencephalopathy.
Ciclosporin Inhibits IL-2–dependent T-
lymphocyte activation by calcineurin
inhibition.
Inhibited EAU manifesting in Lewis rats and
guinea pigs.e53,e54 Inflammation control and
steroid-sparing effect.e55,e56
Seizures and encephalopathy.
Optic disc swelling reported.
Tacrolimus Inhibits IL-2–dependent T-
lymphocyte activation by calcineurin
inhibition.
Inhibited EAU in rats.e57 Inflammation control




Cyclophosphamide Alkylating agent, cross-linking DNA
strains leading to reduced DNA
synthesis.
Cyclophosphamide inhibited EAU in mice.e49
Inflammation control and steroid-sparing
effect in uveitis.e59,e60
Reversible posterior
leukoencephalopathy syndrome in <1%





mAb to TNF-alpha. Anti–TNF-alpha serum inhibited EAU inmice.e61
Strong evidence of inflammation control and
steroid-sparing effect in uveitis.e62-65
Nonspecific neurologic side effects.
Rare side effects include Guillain-Barre
syndrome, stroke, optic neuritis, and
demyelination.
Secukinumab mAb inhibiting IL-17A. Anti-IL17 mAb inhibited EAU development in
rats but lower efficacy in uveitis.e66,e67
No directly neurotoxic side effects
reported.
Tocilizumab mAb inhibited IL-6 by binding to IL-
6R.
Anti-IL6R mAb inhibited EAU in mice.e68
Moderate evidence for inflammation control
in uveitis.e69
Demyelination in a patient previously
treated with anti-TNF.e70
Interferons Interferons alpha and beta are
cytokines with pleiotropic effects
and an important role in interfering
with viral replication.
IFN beta reduced the severity of EAU in rats.e71
Moderate evidence of effect of interferon
alpha.e72,e73 There is limited evidence for a
therapeutic effect from interferon-beta.e74
Interferons alpha and beta cause mood
changes, confusion, sleep impairment,
memory changes, stroke, hallucinations,
and psychosis.
Abbreviations: EAU = experimental autoimmune uveitis; IL-6 = interleukin 6; mAb = monoclonal antibody.
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fingolimod treatment, with a second evaluation at 3–4
months.48 Symptoms of fingolimod-induced macular edema
are identical to macular edema associated with IU and similar
to CSCR but resolve following the withdrawal of fingolimod.
Hence, OCT imaging is indicated in patients with MS who
develop visual distortion or central visual loss to differentiate
between the complications of IU, DMDs like fingolimod, and
corticosteroid treatment (figure 3).
Similarly, all of the immunomodulatory treatments used to
treat IU can cause neurologic side effects, and many of these
could be confused with the onset of MS symptoms (table 2).
Nonspecific neurologic symptoms such as confusion, dizzi-
ness, paresthesia, and muscle weakness are common. Fur-
thermore, complications arise because of increased
immunosuppression and the associated risks of JC viral in-
fection and neoplasia.
An additional concern among ophthalmologists is the risk of
precipitating new-onset demyelination and MS following
treatment with biologic therapies. Experimental evidence that
anti-TNF agents were effective in EAE led to clinical trials that
paradoxically showed anti-TNF agents precipitated and ex-
acerbated demyelination in patients with MS (figure 3G).49
There are also reports of CNS demyelination in patients with
rheumatoid arthritis treated with tocilizumab.42,50 Why anti-
TNF and anti–IL-6 receptor agents might precipitate de-
myelination in people not known to have MS or exacerbate
demyelination in those who do is unclear, but underline the
caveats of evidence derived from animal models. Conse-
quently, ongoing caution and surveillance are required when
using biological therapies to treat uveitis.
Recommendations for management of MS-
associated IU
There are several challenges for clinicians managing patients
with MS and IU. First, it is difficult to detect uncomplicated IU
in patients with MS without ophthalmic equipment or exper-
tise. Second, the complications of chronic intraocular in-
flammation, e.g., cataract, glaucoma, and macular edema, are
also complications of treatments for MS and IU, e.g., cortico-
steroids and fingolimod. In addition, several DMDs for MS
cause visual side effects that could be confused with episodes of
demyelination and the complications of IU or its treatment.
Likewise, treatments for uveitis can cause neurologic side ef-
fects and demyelination. Multidisciplinary team working be-
tween ophthalmologists and neurologists is, therefore, key to
ensuring better treatment outcomes for patients with MS
and IU.
In patients withMSwho are naive to DMDs, the development
of IU is not an indication to start DMDs; management should
be tailored to that required for uveitis. In patients with MS
already on DMDs, local therapies for IU such as intravitreal
dexamethasone implants are likely to work best to treat local
inflammation while avoiding additional systemic side effects
from escalating immunomodulatory treatment. Decisions
regarding changes to DMDs for MS would also benefit from
ophthalmology input to optimize the management of both
conditions.
For patients with IU treated with anti-TNF agents who later
develop demyelination, it is not clear whether these de-
myelinating episodes would have occurred in these patients
regardless of whether they were treated with anti-TNF agents
Table 3 Management recommendations for patients with intermediate uveitis and/or MS
Patients with MS with no history of IU
Normal practice: refer for an ophthalmic assessment if new symptoms develop of visual blurring, distortion, floaters, or red eye to evaluate whether uveitis
or complications of DMDs are the cause of symptoms.
Patients with MS who later develop IU
Consider local therapies for IU, such as an intravitreal steroid implant, to control intraocular inflammation. Role for MDT to discuss optimummanagement
of dual pathology.
Patients with IU with no history of MS
Normal practice: refer for neurology opinion if new neurologic symptoms or signs develop.
Recommend MRI of the brain to screen for white matter lesions consistent with demyelination if considering starting an anti-TNF agent. Radiologically
isolated syndrome is a relative contraindication for anti-TNF treatment: refer to a neurologist to assess any new signs of possible demyelination.
Patients with IU who later develop demyelination
If already on anti-TNF treatment, this should be stopped. Refer to a neurologist for the assessment of demyelination and appropriate treatment.
Monitor IU and adjust management based on any therapy initiated by a neurologist. Role for MDT to discuss optimum management of dual pathology.
Patients with MS and IU demonstrating progression on treatments recommended above.
Role for MDT to consider use of therapies with potential for dual benefit in both conditions, e.g., interferon-beta, glatiramer, antimetabolites
(mycophenolate and azathioprine), or biologics such as natalizumab, alemtuzumab, rituximab, and ocrelizumab.
Abbreviations: IU = intermediate uveitis; MDT = multi-disciplinary team.
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or not. This is because it is still not known whether IU is an
early manifestation of MS or whether demyelination is purely a
complication of anti-TNF treatment in those who would never
have developed demyelination otherwise. Our recommenda-
tion is that all patients with IU have a brain MRI scan to
determine their risk of developing clinically relevant de-
myelination before the introduction of anti-TNF therapy. For
those patients with white matter lesions suggestive of de-
myelination (figure 3G), we consider anti-TNF therapy to be
contraindicated pending further neurologic assessment, and all
other treatment options for uveitis should be explored instead.
In patients with coexistent MS and IU, based on our current
understanding of their pathophysiology, informed by disease
models, case reports, and clinical trials, it is possible to make
tentative recommendations for treatments that target specific
aspects of the immune response common to both conditions.
There is evidence pointing to the dual efficacy of IFNβ,
glatiramer acetate, MMF, natalizumab, alemtuzumab, and
anti-CD20 therapies in the treatment of both MS and IU,
suggesting that treatments, which target leukocyte trafficking,
B cells, or effector T cells in the peripheral circulation, may be
most effective (table 3). However, there is a need for addi-
tional clinical trials in this area.
Conclusions
MS and IU are both immune-mediated inflammatory diseases
affecting immune-privileged sites in the eye and brain. Both
disorders share similar immunopathogenic mechanisms, and,
consequently, many of the same treatments are effective in the
treatment of acute relapses and chronic inflammation in MS
and IU, with the clear exception of anti-TNF therapies. An
important consideration is that many of the treatments forMS
and IU can cause visual and neurologic side effects and
complications that may be confused with progression of either
disease without careful examination, imaging and multidisci-
plinary team working between ophthalmologists and neurol-
ogists. However, there is a need for additional clinical trials to
optimize management.
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